Introduction {#s1}
============

Proliferating cells increase their glucose consumption and secrete lactate as opposed to completely oxidizing the glucose in the mitochondria ([@bib54]) and is known as aerobic glycolysis or the Warburg Effect. Currently, this altered metabolism is exploited for diagnostics and is subjected to multiple drug development efforts ([@bib25]; [@bib50]; [@bib18]). Numerous studies have identified genes such as *KRAS*, *PIK3CA*, and *cMYC* and microenvironments such as hypoxia and hypoglycemia that promote aerobic glycolysis but a complete understanding of the necessary and sufficient biochemical alterations associated with this phenotype is unknown. Furthermore successful translation for biomedical applications is limited by understanding the contexts in which therapies that target glycolysis might be effective.

Computational modeling has a successful history in the study of metabolism ([@bib39]; [@bib12]; [@bib41]; [@bib4]). Genome-scale stoichiometric models of metabolism have been developed to study the effects of drug targets in human metabolism and have had success in predicting the WE ([@bib34]; [@bib53]; [@bib13]; [@bib47]). However, a comprehensive quantitative understanding of the WE requires knowledge of enzyme activities and metabolic control.

Therefore, we collected and integrated multiple forms of data into a modeling framework involving flux balances of glycolysis, detailed chemical kinetics based on reaction mechanisms and parameters measured, physico-chemical constraints from thermodynamics and mass conservation, metabolic control analysis, and Monte Carlo sampling of parameter space. We next use mass spectrometry and isotope tracing to probe concentrations and fluxes through the pathway and their responses to several perturbations. Together, we elaborate the determinants of aerobic glycolysis and identify and confirm novel points of regulation in glycolysis that have remained unidentified for over 50 years since the discovery of the pathway.

Results {#s2}
=======

Biochemical kinetic model of aerobic glycolysis {#s2-1}
-----------------------------------------------

We investigated the kinetics of the glycolytic pathway from glucose uptake to oxidation of pyruvate in the mitochondria or export of lactate out of the cytosol. We modeled each step of the pathway according to enzymatic mechanism and known modes of allosteric control resulting in a set of differential equations ([Figure 1A](#fig1){ref-type="fig"}, 'Materials and methods', [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). While it is not possible to model every possible interaction explicitly, the aim is to capture enough of the pathway so that a large range of experimentally realized measurements can be obtained and relationships between variables can be observed.10.7554/eLife.03342.003Figure 1.A quantitative model and statistical simulation method captures the diversity of metabolic states observed in tumor and proliferating cells.(**A**) Schematic of the glycolysis model with chemical reactions and allosteric points of regulation described. Abbreviations: GLC---glucose, G6P---glucose-6-phosphate, F6P---fructose-6-phosphate, FBP---fructose-1,6,-bisphosphate, F26BP---fructose-2,6,-bisphosphate, GAP---glcyceraldehyde-3-phosphate, DHAP---dihydroxyacetone phosphate, BPG---1,3 bisphosphoglycerate, 3PG---3-phosphoglycerate, 2PG---2-phosphoglycerate, PEP---phosphoenolpyruvate, PYR---pyruvate, SER---Serine, GLY---glycine, Lac---lactate, MAL---malate, ASP---aspartate, Pi---inorganic phosphate, CI---creatine, PCI---phosphophocreatine, GTR---glucose transporter, HK---hexokinase, PGI---phosphoglucoisomerase, PFK---phosphofructokinase, ALD---aldolase, TPI---triosephosphoisomerase, GAPDH---glyceraldehyde-phosphate dehydrogenase, PGK---phosphoglycerate kinase, PGM---phosphoglycerate mutase, ENO---enolase, PK---pyruvate kinase, LDH---lactate dehydrogenase, MCT---monocarboxylate transporter, PDH---pyruvate dehydrogenase, CK---creatine kinase. (**B**) Overview of the algorithm and simulation method. (**C**) Measured values of the NADH/NAD^+^ ratio across a population of MCF10A breast epithelial cells. Three values of glucose concentration are considered (0.5 mM blue, 5.5 mM green, and 25 mM red). (**D**) Calculated fluxes (mM/hr) for glycolysis rate (Glycolysis) are defined as the rate of glucose to pyruvate (per molecule of pyruvate), pyruvate to lactate flux (LDH), rate of oxygen consumption (OxPhos), rate of NADH turnover (NADH), and ATP turnover (ATPase). (**E**) Calculated probability density function (PDF) of NAD^+^ concentrations. (**F**) Calculated probability density function (PDF) of NADH/NAD^+^ ratio. (**G**) Calculated probability density function (PDF) of ATP concentrations. (**H**) Calculated probability density function (PDF) of ATP/ADP ratio. (**I**) Box plots showing the distribution of concentrations computed from the simulation for each intermediate in glycolysis.**DOI:** [http://dx.doi.org/10.7554/eLife.03342.003](10.7554/eLife.03342.003)

Since glycolysis is the most extensively studied biochemical pathway, there is a wealth of information on the kinetic parameters and enzyme expression that govern the equations. Nevertheless, it is also not possible to capture cellular physiology in any biochemical model with single values of kinetic parameters ([@bib9]). This difficulty arises from the tremendous amount of heterogeneity within cells at multiple levels. The origins of this heterogeneity vary from genetic variation observed across cancer types, tumor types, differences in signaling mechanisms that affect post-translational modifications in each cell, and the differences in microenvironmental pressures (e.g., the oxygen availability) that each cell within a given tumor experiences, as well as the inherent cell to cell variation common to all cells ([@bib31]). Therefore, we developed an integrated algorithm to evaluate the statistics of the kinetics of glycolysis that accounts for the possible variation within metabolism ([Figure 1B](#fig1){ref-type="fig"}, 'Materials and methods').

First the model is constrained using mass conservation constraints that conserve the balance of glucose, redox state, and energy status. Next, thermodynamic constraints are used to constrain fluxes according to the free energy of the reactions determined by Haldane relationships. These physical constraints are combined with the kinetic mechanisms that define each step of glycolysis and the chemical reactions involving the redox-associated metabolites NAD^+^, and NADH and energy-associated metabolites ATP, ADP, and AMP. Next, the model is constrained to expression data so that protein concentrations are subsumed in the Vmax values and chosen from typical concentrations in cancer cells, measured kinetic parameters, and measured concentrations of nutrients such as glucose, oxygen, and total intracellular adeno-nucleotide concentration.

At this stage, the model is subjected to a thorough statistical analysis. A Monte Carlo simulation is conducted for which the parameters within the model are randomized and resulting differential equations are solved. The distributions for each parameter are chosen to capture observed ranges of variation. After each simulation, numerical stability and thermodynamics are assessed and all simulations that are unstable or appear thermodynamically infeasible (i.e., a positive net flux through glycolysis is required) are rejected. In each simulation, concentrations, fluxes, metabolic control coefficients, and thermodynamic quantities are computed and recorded. This statistical analysis explores the space of glycolysis in the context of the Warburg Effect. By assessing the statistics, inferences can be made on the determinants of the Warburg Effects and its context dependence to pharmacological intervention and nutrient environment. For experimental confirmation of the model, we first utilized a recently developed a NADH/NAD^+^ fluorescent reporter ([@bib21]) and measured the ratio of NADH/NAD^+^ across a population of cells where some experience hypoxia and others glucose deprivation ([Figure 1C](#fig1){ref-type="fig"}). This variation in nutrient availability across individual cells occurs in epithelial cell cultures due to differences in diffusion and available cell surface area ([@bib46]). The distribution is plotted for three media concentrations ranging from extreme hypoglycemia to the hyperglycemic conditions typically used in cell culture (0.5 mM, 5.5 mM, and 25 mM).

Next we noted that the distribution of resulting fluxes ([Figure 1D](#fig1){ref-type="fig"}) was first found consistent with known measurements. An analysis of the simulation revealed a distribution of NAD^+^ levels and NADH/NAD^+^ redox potential consistent with those observed experimentally ([Figure 1E,F](#fig1){ref-type="fig"}). ATP levels peaked around 3 mM with little variation ([Figure 1G](#fig1){ref-type="fig"}) and the ATP/ADP energy state is observed to be bimodal ([Figure 1H](#fig1){ref-type="fig"}). Concentrations along the glycolytic pathway varied with means similar to those measured in normal tissues with fructose-1,6-bisphosphate (FBP) being most variable ([Figure 1I](#fig1){ref-type="fig"}). Together, these findings indicate that these simulations capture the range of measured cellular concentrations and provide confidence for further assessment of the behavior within the model.

Evaluation of the Warburg Effect and its relationship to metabolic variables {#s2-2}
----------------------------------------------------------------------------

Having developed a model of glycolysis and its regulation, we assessed the relationship of aerobic glycolysis to other characteristics of glycolysis. The distribution of values ([Figure 2A](#fig2){ref-type="fig"}) of the Warburg Effect (the ratio of flux to lactate over that entering the mitochondria) ranged from less than one (primarily oxidative metabolism) to over 95% of glucose being converted to lactate. The dynamic range over which the Warburg Effect was observed in our model allowed us to investigate to other variables in metabolism. We correlated the calculated value of the Warburg Effect with metabolite concentrations of intermediates in glycolysis. From an analysis of these correlations, a pattern within glycolysis emerges. The levels of intermediates in the beginning steps in glycolysis positively correlate with the Warburg Effect, the levels leading up to the oxidation of glyceraldehyde-3-phopshate (GAP) by GAPDH negatively correlate with the Warburg Effect, and those following GAPDH positively correlate with the Warburg Effect ([Figure 2B](#fig2){ref-type="fig"}) suggesting together that a bottleneck exists in the pathway that determines the extent of fermentation. An analysis of the correlation of enzyme expression with the Warburg Effect revealed that the enzyme expression for any single step within glycolysis did not completely correlate with the Warburg Effect. However, across glycolysis, GAPDH, the enzyme that carries out oxidative phosphorylation of glyceraldehyde-3-phosphate to yield NADH and 1,3-diphosphoglycerate most strongly correlated with aerobic glycolysis ([Figure 2C](#fig2){ref-type="fig"}). Notably many of the correlations although significant, appear not very strong indicating that the expression of individual enzymes is not sufficient for induction of aerobic glycolysis. The model also captures many of the activities that are known to correlate with aerobic glycolysis. These include glucose transport, pyruvate kinase, and lactate dehydrogenase activities. Interestingly, the expression of enzymes such as hexokinase and phosphofructokinase were either uncorrelated or negatively correlated with the extent of aerobic glycolysis likely indicating their role in creating bottlenecks at other points along the pathway. Together, these findings identify enzyme expression patterns that determine the extent of the Warburg Effect.10.7554/eLife.03342.004Figure 2.Evaluation of the statistics of the Warburg Effect and relationships to other variables in metabolism.(**A**) Probability density function (PDF) of the Warburg Effect (WE) defined as the ratio of flux through LDH to that of flux into the mitochondria. (**B**) Pearson correlations of intermediate metabolite levels in glycolysis with the extent of the Warburg Effect (WE). (**C**) Pearson correlations of the expression levels of glycolytic enzymes with the extent of the Warburg Effect (WE). (**D**) Pearson correlations of coupled metabolic parameters with the extent of the Warburg Effect (WE).**DOI:** [http://dx.doi.org/10.7554/eLife.03342.004](10.7554/eLife.03342.004)

We next investigated the relationship between the Warburg Effect and other physiological variables including the NADH/NAD^+^ redox status, the energy state defined as the ATP/ADP ratio, lactate, oxygen levels, and phosphocreatine levels ([Figure 2D](#fig2){ref-type="fig"}). Oxygen concentration, ATP, and phosphocreatine levels positively correlated with the Warburg Effect and NADH/NAD^+^ redox status and NADH levels in the cytosol negatively correlated with the Warburg Effect suggesting that positive and negative feedback inherent to the circuitry of glycolysis contributes to buffering the Warburg Effect. Together, these results identify multiple relationships between the extent of aerobic glycolysis and measurable variables in metabolism.

Flux control in glycolysis {#s2-3}
--------------------------

After assessing how metabolic parameters and concentrations within glycolysis determine the flux to lactate, we next investigated how each node within glycolysis exerts its control on the Warburg Effect. Metabolic control analysis (MCA) provides a mathematical framework for evaluating the extent that a change in metabolic activity affects a given flux. In MCA, a pure rate-limiting step occurs when the flux control coefficient (FCC) (Supplementary Information) is one at that step and zero at all other steps. In most cases, values of FCCs are distributed with gradual values across a pathway. We carried out a metabolic control analysis using MCA within our statistical algorithm to investigate the influence of each node in glycolysis on lactate flux across the ensemble of statistical realizations of glycolysis ([Figure 3A](#fig3){ref-type="fig"}). We first computed the distribution of FCCs for lactate production for each step in the pathway ([Figure 3B](#fig3){ref-type="fig"}). It was found that for each step within glycolysis, the average control exerted was near zero. Steps early in glycolysis involving enzymes Hexokinase (HK), Phosphoglucoisomerase (PGI), and Phosphofructokinase (PFK) exhibit both positive and negative control, and GAPDH on average exhibits the most positive control on the flux through the pathway. In addition to steps within glycolysis, ATPase activity exerts the most influence over lactate production with oxygen consumption having less of an affect. Together, these results both confirm the long-standing hypothesis that ATPase activity is the most prominent rate-determining step in glycolysis but also suggest that GAPDH can often exert a large control on the flux to lactate. In addition, an analysis of the statistics indicates that depending on the context, any point along the pathway can exert large flux control on lactate production with some steps (e.g., pyruvate kinase) less likely to exert control over the Warburg Effect than others. Although the finding that pyruvate kinase typically does not exert substantial control over glycolysis may appear surprising, this finding is consistent with studies that have observed only modest changes in glycolytic flux due to changes in pyruvate kinase activity ([@bib7]; [@bib22]).10.7554/eLife.03342.005Figure 3.Metabolic control analysis and its relationship to metabolic variables.(**A**) Schematic of workflow for global sensitivity analysis. After the model is constructed and feasible solutions obtained, each realization of glycolysis is subjected to metabolic control analysis (MCA). The resulting analysis is then subject to a statistical evaluation. (**B**) (left) Box plots of flux control coefficient (FCC) for lactate production for each enzymatic step in glycolysis (FCC = dlnJ~lac~/dln E~i~) where J~lac~ is the rate of pyruvate conversion to lactate, and E~i~ is the i^th^ enzyme in glycolysis for each step of glycolysis. (right) Box plots of flux control coefficient (FCC) for lactate production for Oxygen consumption (OxPhos) and ATP consumption (ATP). (**C**) Pearson correlations between lactate FCC values for each step in glycolysis. Heat map is colored ranging from the minimum value (green) to the maximum value (purple). (**D**) Pearson correlations between metabolite concentrations in glycolysis and lactate FCC values for each step in glycolysis. Heat map is colored ranging from the minimum value (green) to the maximum value (purple). (**E**) Pearson correlations between metabolic parameters and lactate FCC values for each step in glycolysis. Heat map is colored ranging from the minimum value (green) to the maximum value (purple). (**F**) Pearson correlations between ratios and lactate FCC values for each step in glycolysis.**DOI:** [http://dx.doi.org/10.7554/eLife.03342.005](10.7554/eLife.03342.005)

To further investigate the contexts in which steps along glycolysis can be limiting, we correlated the FCCs with one another and carried out a hierarchical clustering that revealed modules of co-occurring flux control ([Figure 3C](#fig3){ref-type="fig"}). It was found that enzymes residing in proximal regions of upper glycolysis tend to have positively correlated flux control. However, for lower glycolysis the flux control is uncorrelated suggesting that when a step is limiting in lower glycolysis, it can be more readily disrupted. This behavior is in contrast with that of upper glycolysis where limiting steps co-occur. Furthermore, an analysis of ATPase and Oxygen consumption activities reveals their control to be related to the control of enzymes clustered at different points in glycolysis ([Figure 3C](#fig3){ref-type="fig"}) indicating that flux control exerted by these ancillary fluxes are tied to different regions of glycolysis. Since these simulations yield for each realization of glycolysis, a set of concentrations, fluxes and flux control coefficients, relationships between flux control coefficients and measurable concentrations can be obtained. An analysis of these relationships using hierarchical clustering ([Figure 3D](#fig3){ref-type="fig"}) revealed a bi-modal relationship in glycolysis where increases in metabolites in upper glycolysis led to steps in lower glycolysis exerting flux control and increases in lower glycolysis resulted in enzymes in upper glycolysis exerting flux control. Further analysis of FCCs and metabolic parameters ([Figure 3E,F](#fig3){ref-type="fig"}) revealed additional relationships. Together, these findings yield a comprehensive map of the flux control in glycolysis and its connections to metabolic variables.

Experimental flux control in glycolysis {#s2-4}
---------------------------------------

Surprisingly, in several instances, negative flux control is observed for several enzymes that have been previously thought to be the rate-limiting steps. Negative flux control implies that inhibiting the enzyme would actually increase the rate of flux of glucose to lactate. Given the surprising findings on flux control in glycolysis, we sought to experimentally investigate these predictions. We therefore considered systematic perturbations to glycolysis in cancer cells.

We first devised a combined flux profiling and metabolite profiling method using ^13^C isotope tracing from glucose ([Figure 4A](#fig4){ref-type="fig"}). Cells were incubated with U--^13^C glucose and media were extracted at different time points and subjected to high resolution LC-MS analysis ([@bib28]). The linearity of the time course allows for an exact measurement of the flux from glucose to lactate. We next carried out direct measurements of glycolysis state and flux control by perturbing glycolysis acutely with pharmacological agents and subsequently measuring metabolite levels and the flux from glucose to lactate. Genetic manipulations such as RNA interference were not possible since the measurement of dose-dependent acute effects was necessary. In each case, the compounds considered have been reported to exhibit direct inhibition of the enzyme in question and to our knowledge do not directly inhibit other enzymes in glycolysis. Nevertheless, the general specificity of these compounds is not established and off target effects that exist are likely reduced by considering acute treatments.10.7554/eLife.03342.006Figure 4.Experimental flux control coefficients.(**A**) Schematic of experimental flux control analysis. Cells are pre-incubated with ^13^C glucose and treated with differing concentrations of inhibitors that target glycolysis at different points in the pathway. Media and intracellular metabolites are collected, subjected to (liquid chromatography high resolution mass spectrometry) LC-HRMS, and subjected to flux analysis. (**B**) Changes in metabolite levels observed from treatment with 3PO an inhibitor of PFK2. (**C**) Changes in metabolite levels observed from treatment with IA an inhibitor of GAPDH. (**D**) Changes in metabolite levels observed from treatment with FX11 and inhibitor of LDH. For **B**--**D**, the logarithm (log~2~) of the fold change of treated to vehicle across intermediates in glycolysis is shown for each concentration of compound denoted in the figure legend. Abbreviations are the same as described in [Figure 1](#fig1){ref-type="fig"} except that HP denotes all hexose phosphates that were measured and not distinguished in the current mass spectrometry method. (**E**) Lactate flux from glucose as a function PFK2 inhibition. (**F**) Lactate flux from glucose as a function GAPDH inhibition. (**G**) Lactate flux from glucose as a function LDH inhibition. For **E**--**G**, the plot on the left shows the measured glucose to lactate flux as a function of the estimated fraction of enzyme inhibited (left) inhibitor concentration (right).**DOI:** [http://dx.doi.org/10.7554/eLife.03342.006](10.7554/eLife.03342.006)

We considered inhibiting glycolysis at three separate points along the pathway that are predicted to have widely variable flux control of the pathway. In the beginning of glycolysis we used 3PO, a compound that targets PFK2 thus inhibiting the phosphofructokinase step ([@bib42]). Next, we considered iodoacetate (IA), a compound that targets GADPH ([@bib3]). Finally FX11, a compound that targets LDH was considered ([@bib17]).

In each case ([Figure 4B--D](#fig4){ref-type="fig"}) differential, complex, nonlinear responses of metabolite levels to inhibiting glycolysis were observed. The exception was treatment with IA ([Figure 4C](#fig4){ref-type="fig"}) which exhibited an expected accumulation of intermediates upstream of GAPDH and depletion of intermediates downstream of the target. We next measured directly the flux control coefficients for each compound. An analysis of the flux control ([Figure 4E--G](#fig4){ref-type="fig"}) revealed several interesting responses. Strikingly, as predicted by the model, a negative flux control was observed for targeting PFK implying that inhibiting this step in these circumstances increases glycolytic flux and Warburg Effect ([Figure 4E](#fig4){ref-type="fig"}). The largest flux control was observed with inhibition of GAPDH ([Figure 4F](#fig4){ref-type="fig"}). Inhibition of LDH as predicted also resulted in little flux control ([Figure 4G](#fig4){ref-type="fig"}). Together, these findings confirm the mechanisms of flux control of glycolysis predicted by the model and demonstrate the novel regulation of glycolytic flux that can be differentially perturbed by pharmacological compounds.

FBP status and signatures of glycolysis state {#s2-5}
---------------------------------------------

We have thus far observed experimentally the dynamic behavior of flux control in glycolysis including both positive and negative flux control in the pathway and a high variability of flux control depending on the point of inhibition in the pathway. Having established the complex relationships between glycolytic flux and susceptibility to specific targeted inhibition of the pathway, we sought to investigate whether there was any predictive capacity and new mechanisms of biochemical regulation related to these findings.

We noticed that Fructose-(1,6)-bisphosphate (FBP) levels exhibited highly dynamic and counterintuitive behavior with each drug perturbation. An analysis of metabolite levels across a series of 14 conditions in triplicate involving pharmacological perturbations of PFK2, LDH, and GAPDH at different concentrations and two separate vehicle treatments ([Figure 5A](#fig5){ref-type="fig"}) revealed large magnitude, dynamic responses in FBP levels. We next investigated the extent that FBP levels could characterize the metabolic state of glycolysis. The simulated PDF of FBP levels exhibited a bimodal distribution ([Figure 5B](#fig5){ref-type="fig"}) consisting of a state of low FBP where the concentration was in the high micromolar range. In addition, there existed a state of FBP where the concentration was several orders of magnitude high in the millimolar range. When demarcating the experiments into two groups (high and low FBP) we correlated the levels with lactate flux experimentally ([Figure 5C,E](#fig5){ref-type="fig"}) and found the results to match those observed computationally ([Figure 5D,F](#fig5){ref-type="fig"}). In addition, correlations in these two states with the remainder of the concentrations of glycolytic intermediates agreed well with experiments. Together these findings suggest in addition to the model being able to capture a diverse set of experimental metabolic conditions, the FBP status in cells was able to determine the state of glycolysis and its rate-limiting steps.10.7554/eLife.03342.007Figure 5.FBP levels predict distinct mechanisms in glycolysis.(**A**) Variation of metabolite levels across glycolysis over 14 conditions in triplicate resulting in 42 independent experiments involving cells growing in basal conditions and those with differing extents of inhibition of glycolysis from results in [Figure 4](#fig4){ref-type="fig"}. (**B**) Simulated distribution of FBP levels in glycolysis. (**C**) Correlation of lactate flux with measured glycolytic intermediates for low FBP levels. The left panel shows data for FBP and right panel reports the values of the Spearman correlation coefficients for each metabolite. (**D**) Simulated correlation of lactate flux with metabolite levels of glycolytic intermediates in conditions of low FBP levels. (**E**) Correlation of lactate flux with measured glycolytic intermediates for high FBP levels. The left panel shows data for FBP and right panel reports the values of the Spearman correlation coefficients for each metabolite. (**F**) Simulated correlation of lactate flux with metabolite levels of glycolytic intermediates in conditions of low FBP levels.**DOI:** [http://dx.doi.org/10.7554/eLife.03342.007](10.7554/eLife.03342.007)

A unified model of aerobic glycolysis {#s2-6}
-------------------------------------

Together, the combined computational model, metabolite profiling, and flux analysis points to a different picture of glycolysis ([Figure 6](#fig6){ref-type="fig"}). When the levels of FBP are low, metabolite levels of glycolytic intermediates tend to be more evenly distributed across the pathway. In this circumstance, flux through the pathway is controlled largely through the initial steps in glycolysis involving hexokinase and phosphofructokinase. Bottlenecks downstream of these canonical rate-limiting steps are not affecting flux through the pathway. Under these conditions, FBP is also not allosterically activating pyruvate kinase. In contrast, when the levels of FBP are high, there is a disconnect in the relative concentration of glycolytic intermediates that is marked by a separation between upper and lower glycolysis at the GAPDH step. In this case, there is an accumulation of intermediates in upper glycolysis, most notably FBP and a depletion of intermediates downstream of GAPDH. Under these circumstances, GAPDH exerts control as the most rate-determining step in the pathway since increased activity through GAPDH will serve then to create a balance along the pathway by pulling the metabolites from upper glycolysis into lower glycolysis. Under these conditions, the beginning steps of glycolysis can exert negative control on the pathway since inhibiting them will result in even greater increases in the intermediates in upper glycolysis. This state has analogies with a recently observed state of glycolysis observed in yeast where an accumulation of FBP leads to cellular toxicity ([@bib52]). Notably in this case, in order to balance the fluxes in higher and lower glycolysis, an imbalance in the concentrations of metabolites in upper and lower glycolysis results.10.7554/eLife.03342.008Figure 6.A unified model of aerobic glycolysis.A unified picture of flux control in aerobic glycolysis. (left) Under conditions where there is an accumulation of intermediates in upper glycolysis and depletion of intermediates in lower glycolysis a bottleneck exists at the step involving GAPDH. This bottleneck is due to the status of energy and redox metabolism and the thermodynamics of the pathway that together mediate the flux through GAPDH. As a result, inhibiting flux through glycolysis is most sensitive to a perturbation in GAPDH activity. (right) Under conditions where the metabolites in glycolysis are distributed more evenly with levels together being either high or low, no such bottleneck exists. Instead flux through glycolysis leading to lactate production is most determined by the canonical pacemaking steps in glycolysis involving PFK and HK. The relative levels of glycolytic intermediates are denoted by the size of the text.**DOI:** [http://dx.doi.org/10.7554/eLife.03342.008](10.7554/eLife.03342.008)

Discussion {#s3}
==========

Together, our analysis yields a comprehensive, quantitative framework for understanding glycolysis and its regulation in the context of the Warburg Effect. Historically, glycolysis is thought to have a rate-limiting step at several points in the pathway ([@bib5]; [@bib55]). These points correspond to positions in the pathway where large free energy differences arise including the ATP-coupled enzymes Hexokinase, Phosphofructokinase, and Pyruvate Kinase ([@bib40]; [@bib39]; [@bib20]). Surprisingly, we identified a strong context-dependence with both positive and negative control in glycolysis at each of these steps. In the case of inhibiting flux through PFK, the observed negative control in certain conditions implies that inhibiting this point in the pathway can lead to increased rates of fermentation. This finding provides a possible explanation for why its efficacy may be more prevalent in stromal cells ([@bib42]).

Unexpectedly, GAPDH was found to be a recurrent rate-controlling step in aerobic glycolysis. This finding, first documented to our knowledge in parasitic bacteria feeding on high glucose ([@bib2]), is in contrast to the longstanding notion that GAPDH is not a rate-determining enzyme in glycolysis with the activity of enzymes such as hexokinase, phosphofructokinase, and pyruvate kinase thought to be more controlling. In the case of GAPDH, the bottleneck occurs due to its unique placement in the pathway where it can be regulated by ATP, NAD^+^, and the levels of glucose-derived intermediates in the pathway that affects the thermodynamics of glycolysis. There are multiple mechanisms that lead to this finding. ATP consumption has previously been reported to control the rate of glycolysis and this effect likely occurs to some extent through GAPDH ([@bib38]; [@bib29]; [@bib30]). NAD^+^ regeneration that is mediated by the malate--aspartate shuttle and lactate dehydrogenase also affects flux through glycolysis ([@bib10]; [@bib29]). In addition, the activity of the pathway upstream and downstream of GAPDH changes the balance of the levels of intermediates in glycolysis and results in driving the thermodynamics of the reactions out of equilibrium also can result in greater flux control ([@bib36]). Each of these mechanisms separately or together acts to allow for GAPDH to exert flux control over the glycolytic pathway.

Enzymes along glycolysis that are believed to control flux have many documented regulatory mechanisms. For example pyruvate kinase and phosphofructokinase have numerous small molecule effectors and post-translational modifications that affect their activities ([@bib35]; [@bib6]; [@bib23]; [@bib56]). It is notable that GAPDH also is subject to multiple forms of regulation including post-translational modifications such as nitrosylation and reactive oxygen species (ROS) that interacts with the catalytic cysteine in GAPDH to inhibit its activity ([@bib16]; [@bib49]; [@bib32]). In the context of ROS, it is tempting to speculate that alterations in ROS could lead to selective modulation of glycolytic flux as has been suggested to occur with pyruvate kinase ([@bib1]). While ROS-mediated inhibition is unlikely in conditions of exponential growth, it may be more apparent in physiological conditions of hypoxia and glucose deprivation with higher concentrations of ROS. Another critical aspect of the flux control that GAPDH exerts over the glycolytic pathway is high expression of GAPDH in cells undergoing aerobic glycolysis. Indeed, reports of quantitative protein abundance in mammalian cells have identified enzymes in the pathway glycolysis as the most highly expressed collective of proteins in cells ([@bib33]). Interestingly, it was found that within glycolysis, GAPDH is often the mostly highly concentrated protein in glycolysis suggesting that the role of this high expression in these cases is to support the increased amount of glycolytic flux in these cells. Nevertheless, although mechanisms that regulate phosphofructokinase and pyruvate kinase for example have been shown to mediate cell growth and proliferation, whether regulatory mechanisms of GAPDH have functional roles in cell growth and proliferation related to aerobic glycolysis is not known.

Two states of glycolysis were observed with different extents of flux control, tendencies for aerobic glycolysis, and concentration patterns along glycolysis. Notably, the FBP levels have implications on the activity of pyruvate kinase that is also allosterically activated by FBP. At low FBP concentration, pyruvate kinase is not activated by FBP but this occurs only in the high FBP state. This finding could have implications in understanding the contexts in which pharmacologically activating pyruvate kinase may have efficacy. Furthermore, it remains to be seen if any signature of these metabolite states could manifest in the alterations of peripheral metabolism involving pathways whose fluxes emanate from glycolysis. If this were the case, then a tempting possibility would be that these states of glycolysis could be predicted from measurements of peripheral metabolites that could be excreted into circulation allowing for the possibility of developing serum biomarkers for the status of glycolysis in tumors beyond what can be resolved with positron emission tomography using radioactive glucose.

Finally, the surge of interest in metabolism and its contribution to pathogenesis has created an expectation that therapeutics that target glucose metabolism will be clinically successful. Targeting glycolysis in metabolism has raised interest but is limited by the development of biomarkers that could determine the contexts in which targeting glucose metabolism in malignancy would be efficacious ([@bib50]; [@bib15]; [@bib51]). From our model analysis, the consequences of inhibiting glycolysis appear enormously complex that limit biomarker development due to the nonlinear mechanisms that determine the response of the pathway to a drug perturbation. Nevertheless, with the development of these predictive models that can capture diverse behaviors of glycolysis, it is worth considering whether they may have predictive capacity in pre-clinical and clinical settings.

Materials and methods {#s4}
=====================

Kinetic model of glycolysis {#s4-1}
---------------------------

The model includes a compartment involving enzymes in glycolysis and additional compartments involving with reactions that are coupled to glycolysis. The following compartments are considered in addition to the enzymes in glycolysis are considered:Glucose uptake through the glucose transporter,Lactate dehydrogenase (LDH) activity and lactate transport through the monocarboxylate transporter (MCT),Oxygen consumption, transport and activity of oxidative phosphorylation (OxPhos),ATP-buffering mechanisms involving adenylate Kinase, creatine Kinase, and ATPase activity,NADH/NAD^+^-mediated mitochondrial shuttles including the Malate--Aspartate Shuttle and the Glycerol-3-Phosphate Shuttle.

More generally glycogen metabolism, pentose phosphate pathway and alanine biosynthesis could also be included but are omitted since the conclusions drawn in this study do not depend on their activities. A schematic representation of the kinetic model and resulting network is shown in [Figure 2A](#fig2){ref-type="fig"}.

We first introduce notation and other conventions. Each symbol indicates the respective concentration. A subscript '0' refers to the steady-state value. Reaction rates are expressed in millimoles per hour per unit intracellular volume. Together with initial state vectors $C_{0} \in R^{N}\,,\, V_{o} \in R^{M}\,$, of metabolites and fluxes respectively.

The dynamics of the system are therefore formulated as initial value problem for ordinary differential equations (ODEs). Starting parameter values based on published data are defined in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Reaction rates are defined through a consideration of the respective enzyme mechanisms with additional feed forward and feed back regulation giving rise to allosteric activation and inhibition.

Therefore, the model is designed to describe: (a) steady-state and dynamic behavior of energy metabolism, including the Warburg effect ($W=\frac{J_{Lac}}{J_{Ox}}$), energy state (ATP/ADP ratio), redox state (NADH/NAD^+^ ratio) together with glucose, lactate, and oxygen supply through exchange fluxes from the intercellular and extracellular compartment, (b) steady states and time courses of all variables of the metabolic network, and (c) effects of metabolic parameter perturbations on the overall system output. Cellular energy homeostasis through ATP is supported by several mechanisms with different relaxation times and regulation mechanisms: (a) directly by glycolysis that converts glucose into intracellular pyruvate, (b) mitochondrial respiration through consumption of pyruvate and oxygen via the TCA cycle, and (c) the buffering effect of creatine kinase that facilitates the reversible reaction of phosphocreatine (PCr) with ADP to produce creatine (Cr) and ATP, and (d) adenylate kinase activity that catalyzes interconversion of adenine nucleotides: 2ADP ⇔ ATP + AMP, and (e) the additional NADH pool produced in cytosol and transported to mitochondria by different shuttle mechanisms. For oxygen consumption, we assumed that mitochondrial respiration (O~2~ consumption) depends on cellular pyruvate and oxygen concentrations and that respiratory chain activity is activated by ADP concentration.

The state of the system is represented by the state vector of time-dependent metabolite concentrations C~n~, (n = 1, ..., N) and includes 27 state variables whose names, balance equations, and steady-state values are presented in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. The model also includes three mass conservations laws, that reduce the number of state variables. The temporal profile of the system is governed by the set of ODE based on the model network that distinguishes media and cellular domains. For the metabolite *i* in the intracellular compartment, the general form is:$${\frac{dC_{i}}{dt} = J_{i}^{tr} + \sum\limits_{j}\nu_{i}^{pj}V_{i}^{pj} - \sum\limits_{k}\nu_{i}^{uk}V_{i}^{uk}},$$where the intracellular concentration of species *i* is *C*~*i*~; $\, J_{i}^{tr}$ is the net transport flux for boundary species *i* between the media and cell; $V_{i}^{pj}$, $V_{i}^{uk}$ are normalized reaction fluxes that produce (*j*) or utilize (*k*) cellular species *i*, $\nu_{i}^{pj}$, and $\nu_{i}^{uk}$ are corresponding stoichiometric coefficients. For extracellular boundary metabolites in the media, the dynamic mass balance has the following general form:$${\frac{dCe}{dt} = \, r_{ie} \cdot J_{i}^{tr}},$$where the concentration of extracellular (*e*) species is *C*~*e*~ and *r*~*ie*~ is the ratio of cell volume to media volume. To ensure that steady states are obtained during perturbations of parameters without loss of generality, we assume that the media boundary metabolites have constant concentrations. The transport of boundary species is taken to be either facilitated (glucose, lactate, serine, glycine) or passive (oxygen). For passive diffusion of oxygen the equation for the net transport flux is:$${J_{O_{2}}^{tr} = k_{O_{2}}\left( {C_{O2e} - C_{O2i}} \right)},$$where $k_{O_{2}}$ is the effective rate constant for passive *O*~2~ diffusion, and $C_{eO2}$ and $C_{iO2}$ are medium and intracellular oxygen concentrations. For facilitated transport, the equation for the net transport flux is:$${J_{i}^{tr} = \,\frac{J_{tr}^{max}\left( {\frac{C_{ei}}{K_{mi}^{tr}} - \frac{C_{i}}{K_{mi}^{tr}}} \right)}{1 + \frac{C_{ei}}{K_{mi}^{tr}} + \frac{C_{i}}{K_{mi}^{tr}}}},$$where *C*~*ei*~ is the extracellular concentration for species *i*, $J_{tr}^{max}$ is the maximal transport rate, and $K_{mi}^{tr}$ is the Michaelis--Menten constant for transport. NADH transport from the cytosol to the mitochondria is mediated by the malate--aspartate and glycerol phosphate shuttles. We modeled the NAD^+^-mediated mitochondrial shuttle flux from NADH to NAD^+^ by assuming that the total shuttle flux is balanced with the NADH-generation reactions involving LDH and PHGDH.$$V_{mas} = V_{ox} + 2V_{phgdh}$$

When possible, in order to minimize the number of parameters, we utilized a 'one-step binding enzyme mechanism' with a rate law of the form ([@bib43]):$$V = \left( \frac{V_{f}^{max}\frac{\prod_{i}C_{si}^{\nu_{i}}}{Kmf} - V_{r}^{max}\frac{\prod_{j}C_{pj}^{\nu_{j}}}{Kmr}}{1 + \frac{\prod_{i}C_{si}^{\nu_{i}}}{Kmf} + \frac{\prod_{j}C_{pj}^{\nu_{j}}}{Kmr}} \right)\chi\left( {\alpha,\iota} \right),$$where $\chi\left( {\alpha,\iota} \right)$ is a control function that accounts for the effects of activation $\alpha$, or inhibition $\iota$. A general form for the control function is ([@bib27]):$$\chi\left( {\alpha,\iota} \right) = \left\{ \begin{matrix}
{\frac{\left\lbrack A \right\rbrack}{\left( {\left\lbrack A \right\rbrack + K_{A}} \right)}in\, case\, of\, activation,\alpha\,\,} \\
{\frac{K_{I}}{\left( {\left\lbrack I \right\rbrack + K_{I}} \right)}\, in\, case\, of\, inhibition,\,\iota} \\
\end{matrix} \right.,$$where $\left\lbrack A \right\rbrack$ and $\left\lbrack I \right\rbrack$ are the concentrations of the activator or inhibitor, *K*~*A*~ and *K*~*I*~ are the corresponding activation and inhibition constants. With this convention, there are 4 (or 5 including the control function) independent parameters for each metabolic flux with a one-step binding mechanism. For fluxes with no allosteric regulation, $\chi\left( {\alpha,\iota} \right) = 1$.

For all metabolic fluxes involving NAD^+^/NADH oxidoreductase activity, we utilized a more complex rate law than that of a one step binding reaction ([@bib8]). We chose to consider a more complicated rate-law since our initial observations indicated that a one-step binding mechanism produced numerical instabilities in the solutions. We therefore considered a general rate law corresponding to a random bi--bi mechanism (for LDH and PHGDH) and a random ter-bi reaction for GAPDH. For example, in its general form the rate law for LDH is:$$V_{ldh} = \frac{V_{fldh}^{max}\frac{PYR \ast NADH}{Kmldhf} - V_{rldh}^{max}\frac{LAC_{i} \ast NAD^{+}}{Kmldhr}}{1 + \frac{PYR}{K_{mpyr}^{ldh}} + \frac{NADH}{K_{mnadh}^{ldh}} + \frac{PYR \ast NADH}{Kmldhf} + \frac{LAC_{i}}{K_{mlac}^{ldh}} + \frac{NAD^{+}}{K_{mnad}^{ldh}} + \frac{LAC_{i} \ast NAD^{+}}{Kmldhr}}.$$

However, it has also been suggested that the enzymatic reaction for oxidoreductase activity proceeds in an ordered fashion resulting in a rate law of the form:$$V_{ldh} = \frac{V_{fldh}^{max}\frac{PYR \ast NADH}{Kmldhf} - V_{rldh}^{max}\frac{LAC_{i} \ast NAD^{+}}{Kmldhr}}{1 + \frac{NADH}{K_{mnadh}^{ldh}} + \frac{PYR \ast NADH}{Kmldhf} + \frac{NAD^{+}}{K_{mnad}^{ldh}} + \frac{LAC_{i} \ast NAD^{+}}{Kmldhr}}$$

When considering this mechanism, it was found that statistical evaluation of the model was robust to changes in the choice of rate law.

The rate equations for each metabolic reaction and metabolic parameters values are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Taking into account additional thermodynamic constraints by invoking the Haldane equation that relates the forward and reverse fluxes and their Vmax values allowed for a further reduction in the number of independent parameters to three parameters per reaction flux. The Haldane equation has the form:$$V_{r}^{max} = \frac{V_{f}^{\text{max}}Kmr}{KmfK_{eq}},$$where *K*~*eq*~ is the reaction apparent equilibrium constant: $K_{eq} = \exp\left( {{- \text{Δ}G^{{^\circ}}}/{RT}} \right)$, where $\text{Δ}G^{{^\circ}}$ is standard reaction Gibbs free energy. $\text{Δ}G^{{^\circ}}$ values for glycolytic reactions are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

We first used two independent sets of experimental data from a compendium of steady-state metabolite concentrations of liver cells and steady-state fluxes of DB1 melanoma cells evaluated using a cultured bioreactor ([@bib24]; [@bib44]). The model was further validated by a comparison of measurements of redox status, assessment of ATP, ADP, and AMP concentrations. Together, those data were able to generate a thermodynamically feasible and experimentally observable model of glycolysis that was then used as the starting point for exhaustive Monte Carlo simulations and coupled metabolic control analysis.

Monte Carlo simulations for global sensitivity analysis {#s4-2}
-------------------------------------------------------

The specific aim of this work is to enumerate the variables within and coupled to glycolysis that determine the extent of aerobic glycolysis. We therefore developed a novel algorithm to assess these features. The algorithm involves a global sensitivity analysis based on a Monte Carlo method. The Monte Carlo analysis allows for sampling of parameter space over a broad range of simultaneous variations of parameters (enzyme expression levels) followed by statistical assessment of the resulting solution. The idea of this method is to inject uncertainty of the parameters in the model by randomly selecting parameter values from uniform probability distributions. This was achieved by a Monte Carlo method using a randomly drawn set of parameters. The range of parameters chosen with uniform sampling was within two orders of magnitudes of each Vmax (which is proportional to enzyme activity level and was in the range of 10 times less and 10 times greater than the initial Vmax value). Such a sampling was chosen to be large enough to cover all feasible solutions of aerobic glycolysis. The sampling was carried out using a Latin Hypercube sampling method ([@bib37]). For each chosen set of random parameter vectors the model was simulated between 2000 and 5000 times and its output was calculated. Briefly, we divided the range of the *i-th* normalized parameter into n (n = 2000--5000) subintervals of equal size. Then, we randomly sample n values (e.g., *p*~*i*~*, i = 1, ..., n*), one from each subinterval, for the *i-th* parameter. We next randomly permuted the n values for each parameter to get the parameter vector. We then evaluated the following: the Warburg Effect value, energy and redox states, metabolite steady-state concentrations and fluxes and flux control coefficients (FCCs). The flux control coefficient that an enzyme *E*~*i*~ exerts on the lactate flux *J*~*Lac*~ is defined as ([@bib19]; [@bib12]; [@bib45]):$$FCC_{i}=\frac{\partial\ln J_{Lac}}{\partial\ln E_{i}}.$$

To compute the FCC values numerically, we considered a perturbation 0.01 times of the enzyme value and then evaluated the change in flux. The model was implemented in Matlab as a system of 27 ordinary differential equations (ODEs) with an ODE solver designed for stiff ODE systems.

Cell culture and metabolite extraction {#s4-3}
--------------------------------------

HCT116 cells were cultured with a growth medium, which contains RPMI 1640, 10% Fetal Bovine Serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin. The cells were obtained as a gift from Lewis Cantley\'s laboratory. The cells were cultured in 37°C with 5% CO~2~. For treatments, the cells were seeded in 6-well plate at a density of 2 × 10^5^ to 5 × 10^5^ cells per well. After overnight incubation, full growth media were removed, and cells were washed with 2 ml PBS before the addition of RPMI media (without glucose), supplemented with 10% dialyzed and heat inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 5 mM 13C-U-glucose (Cambridge Isotope Laboratory, Tewksbury, MA) (fresh growth media). For drug treatments and flux measurements, full growth media were replaced with fresh growth media, containing either 0.1% DMSO, or the concentration of the indicated drug. Media were then collected at 30, 60, 90, and 120 min after incubation. From 20 µl media, 80 µl of ice cold H~2~O was added, together with 400 µl ice cold methanol (Fisher, Optima LC/MS grade). After vigorous vortexing, the solution was then centrifuged at 20,000×*g* at 4°C for 10 min and then the supernatant was dried under vacuum. At 120 min, the media were removed as completely as possible, and then 6-well plates were immediately placed on dry ice, followed by the addition of 1 ml extraction solvent, 80% MeOH/H~2~O (Fisher, Optima LC/MS Grade), which was pre-cooled in −80°C freezer for at least 1 hr. The dishes were then transferred to the −80°C freezer. The plates were left for 15 min and then cells were scraped into the solvent on dry ice and then transferred to two 1.7-ml eppendorf tubes, and centrifuged with the speed of 20,000×*g* at 4°C for 10 min. Metabolite extracts are prepared from three separate wells to make three replicate samples. The supernatant is then transferred to new eppendorf tubes, and dried under vacuum. For analysis, each extract was then re-constituted into water (15 μl for cell extract and 50 μl for medium extract) and then diluted with an equal volume of 50% Methanol/Acetonitrile. Finally, 5 μl was injected into the column for analysis.

Flux analysis {#s4-4}
-------------

Absolute concentrations of ^13^C lactate were first measured by mixing a standard of unlabeled lactate with a defined concentration into the medium. For each calculated flux, an estimation of the flux from glucose to lactate was obtained from the slope of the time course of ^13^C lactate production using the time points of media collection described above. Slopes were computed using Graphpad Prism with time courses determined to be linear from the goodness of fit (R^2^ \> 0.98 with few exceptions). For corresponding plots for different agents, fraction of inhibition was computed from *K*~*i*~ values that were taken based on previous reports ([@bib14]; [@bib26]; [@bib48]).

Mass spectrometry {#s4-5}
-----------------

The Q Exactive Mass Spectrometer (QE-MS) is equipped with a heated electrospray ionization probe (HESI), and the relevant parameters are as listed: heater temperature, 120°C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for positive mode, and 2.5 kV for negative mode. Capillary temperature was set at 320°C, and S-lens was 55. A full scan range from 60 to 900 (*m/z*) was used. The resolution was set at 70,000. The maximum injection time was 200 ms with typical injection times around 50 ms. These settings resulted in a duty cycle of around 550 ms to carry out scans in both positive and negative mode. Automated gain control (AGC) was targeted at 3,000,000 ions.

Liquid chromatography {#s4-6}
---------------------

Liquid chromatography (Ultimate 3000 UHPLC) is coupled to the QE-MS for metabolite separation and detection. An Xbridge amide column (100 × 2.1 mm i.d., 3.5 μm; Waters) is employed for compound separation. The mobile phase A is 20 mM ammonium acetate and 15 mM ammonium hydroxide in water with 3% acetonitrile, pH 9.0, as described above, and mobile phase B is acetonitrile. A linear gradient was used as follows: 0 min, 85% B; 1.5 min, 85% B; 5.5 min, 35% B; 10 min, 35% B; 10.5 min, 35% B; 14.5 min, 35% B; 15 min, 85% B; and 20 min, 85% B. The flow rate was 0.15 ml/min from 0 to 10 min and 15 to 20 min, and 0.3 ml/min from 10.5 to 14.5 min. All solvents are LC-MS Optima grade and purchased from Fisher Scientific.

NADH/NAD^+^ imaging {#s4-7}
-------------------

Human mammary epithelial MCF-10A cells (CRL-10317; ATCC) stably expressing Peredox-NLS were generated and cultured as previously described ([@bib11]; [@bib21]). 2--4 days prior to imaging, ∼500 cells were plated onto the center of each well of a 96-well plate. On the day of the experiment, cells were placed in custom DMEM/F12 (Gibco) containing no glucose and supplemented to the levels mentioned. Fluorescence images were acquired using a Nikon inverted Eclipse Ti microscope, equipped with a Nikon 20×/0.75 Plan Apo objective, three different regions of interest chosen, images sequentially acquired every 8 min with 50--100 ms exposure and 2 × 2 binning. Using a custom MATLAB algorithm previously developed, we subtracted background, set a threshold for cell segmentation, and analyzed the data as previously described ([@bib21]). The concentration of glucose is maintained by considering a culture system in which cells are seeded at low density and media are present in vast excess. An estimate of glucose maintenance in the media in the low glucose condition can be considered using values the glucose uptake rate of the cells (∼100 fmol/cell/hr), the cell number (∼2000), the volume of media used (400 μl), and concentration of glucose in the media (750 μM, 500 μM from supplementation + 250 μM from the Horse Serum). Thus in 24 hr, we estimate that about 5 nmols of glucose are consumed. The media contain roughly 200 nmols of glucose which is in excess of the amount consumed by the cells.

Data analysis {#s4-8}
-------------

Raw data collected from the QE-MS is processed using Sieve 2.0 (Thermo Scientific). Peak alignment and detection are performed according to the protocol described by Thermo Scientific. For a targeted metabolite analysis, the method 'peak alignment and frame extraction' is applied. An input file of theoretical *m/z* and detected retention time known metabolites is used for targeted metabolite analysis with data collected in both positive and negative mode. *m/z* width is set at 10 ppm. The output file including detected *m/z* and relative intensity in different samples is obtained after data processing. For resulting simulation data, hierarchical clustering was carried out using spearman ranked correlations and the Gene-e software package (Broad Institute). Box-plots (25%/75% percentile, mean and median) was calculated and made with the Graphpad Prism software package.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "A quantitative model of aerobic glycolysis identifies GAPDH as a rate-limiting step" for consideration at *eLife.* Your article has been favorably evaluated by Charles Sawyers (Senior editor), 2 experts in the field of cancer metabolism, as well as a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

All the reviewers and editors agree that the work is interesting as it addresses how glycolytic rate is controlled, a question lacking conclusive answers. The experiments are rigorous and the results are for the most part convincing. However, there are a number of concerns that need to be addressed before the manuscript can be accepted.

1\) An important conclusion is that GAPDH exerts a surprising level of control over glycolytic rate and thus it would be important to expand upon how GAPDH constrains flux. Is the bottleneck imposed simply by reduced levels of enzyme expression, in which case over-expressing the enzyme should produce major changes in metabolite levels and overall flux? Or are other effects at work, such as ROS-mediated inhibition, which has been observed in several systems?

2\) A concern is that the specificity of the glycolytic inhibitors used is questionable. This is a general issue for the field and not easily addressed by these authors, but should be acknowledged in interpreting the experiments.

3\) Measuring glucose consumption directly would be a more straightforward way to assess changes in overall glycolytic flux, and addresses aspect of the Warburg effect (increased glucose uptake) that is not considered by this work.

4\) Distributions of NADH/NAD+ ratios are presented for cells at different glucose concentrations, but how glucose concentrations were maintained in culture over a 24-hour experiment is not clear. Particularly for the 0.5 mM glucose sample, was the concentration of glucose still 0.5 mM when ratios were measured? This seems unlikely.

5\) A straightforward explanation for why GAPDH activity predicts lactate production is that these steps are linked by NAD+ use and regeneration. Even in the absence of modeling a consideration of glycolysis suggests this relationship yet it is hardly mentioned. This point needs to be discussed.
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Author response

1\) An important conclusion is that GAPDH exerts a surprising level of control over glycolytic rate and thus it would be important to expand upon how GAPDH constrains flux. Is the bottleneck imposed simply by reduced levels of enzyme expression, in which case over-expressing the enzyme should produce major changes in metabolite levels and overall flux? Or are other effects at work, such as ROS-mediated inhibition, which has been observed in several systems?

The reviewers raise important points that warrant further discussion. We first note that many different mechanisms can lead to changes in GAPDH activity. For example, one instance was investigated in [Figure 4](#fig4){ref-type="fig"} in which flux control over glycolysis was measured by direct inhibition by a small molecule of GAPDH in which case it was shown to cause the largest decrease in glycolytic flux as opposed to inhibition at other steps of the pathway.

Furthermore, increases in GAPDH expression are also predicted to increase flux through the pathway although as the model predicts the correlation is small (R2 ∼0.4) so this will not always be the case. In fact, GAPDH is the most abundant enzyme in glycolysis suggesting that in many cases the expression of glycolytic enzymes is designed to achieve optimal flux through the pathway (see Moghaddas, Cell Reports 2013, now cited in the text). An increase in activity can occur through multiple mechanisms including the alleviation of its inhibition by ROS or other mechanisms, increasing its activity through allosteric activation, or by increasing its expression which proportionately increases the enzyme activity through increasing Vmax. Together each of these possibilities would manifest themselves in different contexts. We have included the mention of these multiple possibilities in the Discussion. A thorough discussion of each of these effects is mentioned in a revised manuscript.

*2) A concern is that the specificity of the glycolytic inhibitors used is questionable. This is a general issue for the field and not easily addressed by these authors, but should be acknowledged in interpreting the experiments*.

We thank the reviewers for raising this important point. We have modified the text to include caveats regarding the specificity of the inhibitors, resulting limitations in the interpretation of the data, and our efforts to minimize these confounding variables.

*3) Measuring glucose consumption directly would be a more straightforward way to assess changes in overall glycolytic flux, and addresses aspect of the Warburg effect (increased glucose uptake) that is not considered by this work*.

We thank the reviewers for this suggestion. In designing this study, we reasoned that a more conclusive measurement of glycolytic flux was the rate at which glucose was being converted to lactate. This measurement accounts for both glucose uptake and production of lactate. We reasoned that glucose uptake alone does not account for the portion of glycolytic flux that is siphoned into biosynthetic pathways or into the mitochondria. Nevertheless, we have also measured additional fluxes (Author response image 1) including glucose uptake rate, and a biosynthesis rate from glucose and found that each does correlate reasonably well with the rate of glucose to lactate. This result is shown below:Author response image 1.Comparison of glucose uptake rate and rate from glucose to lactate production. A) Diagram of flux experiment. Flux from glucose to pyruvate (e.g. glucose uptake), serine (biosynthetic flux), and lacate (Warburg Effect) is measured. ^13^C glucose is input as described in the methods. B) Comparison of fluxes for 3PO (PFK2 inhibition) treatment C) Comparison of fluxes for IA (GAPDH inhibition) treatment. D) Comparison of fluxes for FX11 (LDHA inhibition) treatment. E) Correlation between flux to serine and flux to lactate across each measurement. F) Correlation between flux to pyruvate and flux to lactate across each measurement.

*4) Distributions of NADH/NAD+ ratios are presented for cells at different glucose concentrations, but how glucose concentrations were maintained in culture over a 24-hour experiment is not clear. Particularly for the 0.5 mM glucose sample, was the concentration of glucose still 0.5 mM when ratios were measured? This seems unlikely*.

We appreciate this concern and have included further clarifications in the Methods. By our calculations shown below and now contained in the Methods, the glucose concentration should be close to constant over the duration of the experiment. The concentration of glucose is maintained by considering a culture system in which cells are seeded at low density and media is present in vast excess. A quantitative estimate of glucose maintenance in the media can be considered using values of the glucose uptake rate of the cells (∼100fmol/cell/hr), the cell number (∼2000), the volume of media used (400 μL), and concentration of glucose in the media (500μM). Thus in 24 hours, we estimate that about 5nmols of glucose are consumed. The media contains about 200nmols of glucose which is in excess of the amount consumed by the cells.

*5) A straightforward explanation for why GAPDH activity predicts lactate production is that these steps are linked by NAD+ use and regeneration. Even in the absence of modeling a consideration of glycolysis suggests this relationship yet it is hardly mentioned. This point needs to be discussed*.

In the Discussion, we have expanded on the mechanisms of GAPDH exerting control over glycolytic rate. The mechanism is partially explained by NAD+ use and regeneration but the full explanation appears more complicated and is due to GAPDH existing at a unique point in the pathway where it can be affected by redox (NAD+/NADH), energy (ATP consumption, and carbon flux (BPG and G3P) that together allow for more points of regulation.

However we respectfully disagree with the reviewers that this finding could be obtained without modeling especially since it was not previously known that GAPDH exerts control over glycolysis. In fact numerous introductory biochemistry textbooks for undergraduate and medical school students have discussed in detail the control of glycolysis and the emphasis has been in these discussions on the steps in glycolysis that involve changes in standard free energies such as pyruvate kinase or phosphofructokinase.
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